{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:17:51Z","timestamp":1789186671939,"version":"build-2803163510"},"reference-count":64,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Chronic kidney disease (CKD) affects approximately 14% of adults in the United States and is present in at least 10% of the population worldwide. Blood glucose and blood pressure control are imperative to adequately manage CKD as they are the only primary prevention measures for the condition. Recent changes in CKD evaluation and medication therapies that modify disease progression and aid in managing complications such as anemia of CKD have emerged, including a newly approved mineralocorticoid receptor antagonist and hypoxia-inducible factor\u2013prolyl hydroxylase inhibitor, respectively. This focused update on CKD evaluation and management will review the most recent evidence and approved agents to support patients with CKD, including a review of glomerular filtration rate measurement methods such as CKD-EPI 2021 and utilization of cystatin C, Kidney Disease Improving Global Outcomes (KDIGO) guidelines, American Diabetes Association (ADA) guidelines, and primary literature supporting the use of newer agents in CKD. Checklists for managing blood pressure and blood glucose, CKD-mineral bone disorder, and anemia of CKD targeted for pharmacists are also provided. Additionally, a discussion of Centers for Medicare &amp; Medicaid (CMS) coverage of agents approved for managing complications of CKD is included.<\/jats:p>","DOI":"10.1177\/08971900241262381","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T02:42:51Z","timestamp":1718419371000},"page":"1380-1390","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Updates in Chronic Kidney Disease"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-8364","authenticated-orcid":false,"given":"Haley N.","family":"Johnson","sequence":"first","affiliation":[{"name":"Pharmacy Practice, St. Louis College of Pharmacy at University of Health Sciences and Pharmacy, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Prasad-Reddy","sequence":"additional","affiliation":[{"name":"Office of Medical Education, Chicago Medical School, Rosalind Franklin University of Medicine & Science, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"bibr1-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"bibr2-08971900241262381","volume-title":"Chronic Kidney Disease in the United States, 2023","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"bibr3-08971900241262381","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S003"},{"key":"bibr4-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30569-X"},{"key":"bibr5-08971900241262381","unstructured":"Saran R, Li Y, Robinson B, et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis;66(Suppl 1):S1-S305."},{"key":"bibr6-08971900241262381","unstructured":"National Kidney Foundation. NKF and ASN release new way to diagnose kidney diseases, 2021. https:\/\/www.kidney.org\/news\/nkf-and-asn-release-new-way-to-diagnose-kidney-diseases#:\u223c:text=NKFandASNrecommenddiagnosing,kidneydiseasesinsomepeople. Accessed 22 Mar 2023."},{"key":"bibr7-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"bibr8-08971900241262381","unstructured":"Chronic Kidney Disease Epidemiology Collaboration. Implementation of the 2021 CKD-EPI GFR equations, 2021. https:\/\/www.tuftsmedicalcenter.org\/-\/media\/Brochures\/TuftsMC\/Research-Clinical-Trials\/Implementation-of-2021-CKD-EPI-Equations-15-Oct-2021-b.ashx?la=enhash=747F5F741555F2A8FC04720D32AC97C1B55CF240. Accessed 15 May 2023."},{"key":"bibr9-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.03.008"},{"key":"bibr10-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00501-8"},{"key":"bibr11-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48940"},{"key":"bibr12-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"bibr13-08971900241262381","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Awdishu L","year":"2023","edition":"12"},{"issue":"3","key":"bibr14-08971900241262381","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease Improving Global Outcomes","year":"2021","journal-title":"Kidney Int"},{"issue":"22","key":"bibr15-08971900241262381","first-page":"2013","volume":"373","author":"The Systolic Blood Pressure Intervention Trial (SPRINT) Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"bibr16-08971900241262381","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0834"},{"key":"bibr17-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054602"},{"key":"bibr18-08971900241262381","volume-title":"Blood Pressure Targets in Adults with Hypertension: A Clinical Practice Guideline from the AAFP","author":"Coles S","year":"2022"},{"key":"bibr19-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004110919"},{"key":"bibr20-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000164577.81087.70"},{"key":"bibr21-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-017-0771-9"},{"key":"bibr22-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.62.s82.11.x"},{"key":"bibr23-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924"},{"key":"bibr24-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02539-2"},{"key":"bibr25-08971900241262381","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"bibr26-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16281"},{"key":"bibr27-08971900241262381","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. 2019;380:2295-2305.","DOI":"10.1056\/NEJMoa1811744"},{"key":"bibr28-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"bibr29-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"bibr30-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1059819"},{"key":"bibr31-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2213888"},{"key":"bibr32-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"bibr33-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"bibr34-08971900241262381","unstructured":"Kerendia. [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2021."},{"key":"bibr35-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"bibr36-08971900241262381","unstructured":"Centers for Medicare & Medicaid Services (CMS). ESRD Quality Incentive Program CMS, 2022."},{"key":"bibr37-08971900241262381","unstructured":"Centers for Medicare & Medicaid Services. (CMS) End-Stage Renal Disease Quality Incentive Program (ESRD QIP) Calendar Year (CY) 2023 measure technical specifications, 2022. https:\/\/www.cms.gov\/medicare\/quality-initiatives-patient-assessment-instruments\/esrdqip\/061_technicalspecifications. Accessed 23 Jun 2023."},{"issue":"4","key":"bibr38-08971900241262381","first-page":"S12","volume":"42","author":"K\/DOQI","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"bibr39-08971900241262381","unstructured":"Velphoro. [package insert]. Waltham, MA: Fresenius Medical Care North America; 2014."},{"key":"bibr40-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.58"},{"key":"bibr41-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv006"},{"key":"bibr42-08971900241262381","unstructured":"Auryxia. [package insert]. Boston, MA: Keryx Biopharmaceuticals Inc; 2017."},{"key":"bibr43-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188712"},{"key":"bibr44-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14396"},{"key":"bibr45-08971900241262381","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15291219"},{"key":"bibr46-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2094273"},{"key":"bibr47-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45335-4"},{"key":"bibr48-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft483"},{"key":"bibr49-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1159\/000344008"},{"key":"bibr50-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080842"},{"key":"bibr51-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"bibr52-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0758-5"},{"key":"bibr53-08971900241262381","unstructured":"Parsabiv. [package insert]. Thousand Oaks, CA: KAI Pharmaceuticals, Inc.; 2017."},{"key":"bibr54-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19468"},{"key":"bibr55-08971900241262381","volume-title":"ESRD PPS Transitional Drug Add-On Payment Adjustment","author":"Centers for Medicare &amp; Medicaid Services (CMS)","year":"2022"},{"key":"bibr56-08971900241262381","unstructured":"Centers for Medicare & Medicaid Services. Calendar year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) final rule (CMS-1768-F), 2022. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/calendar-year-2023-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1768-f. Accessed 2 June 2023."},{"key":"bibr57-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"issue":"4","key":"bibr58-08971900241262381","first-page":"1","volume":"2","author":"Kidney Disease Improving Global Outcomes","year":"2012","journal-title":"Kidney Int"},{"key":"bibr59-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2020.12.002"},{"key":"bibr60-08971900241262381","unstructured":"Jesduvroq. [package insert]. Durham, NC: GlaxoSmithKline; 2023."},{"key":"bibr61-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113379"},{"key":"bibr62-08971900241262381","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13385"},{"key":"bibr63-08971900241262381","volume-title":"Final Summary Minutes of the Cardiovascular and Renal Drugs Advisory Committee Meeting October 26, 2022","author":"Seo J","year":"2022"},{"key":"bibr64-08971900241262381","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0244022"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241262381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241262381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241262381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:32Z","timestamp":1777509212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241262381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/08971900241262381"],"URL":"https:\/\/doi.org\/10.1177\/08971900241262381","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}